Milagros Samaniego-Picota, MD
Nephrology · Roswell, NMNPI 1790746154
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $6,580 of the $10,885 with a category attached, or 60.5%. 14 manufacturers reported payments, led by Otsuka Pharmaceutical Development & Commercialization, Inc. at 37.5% of the total. Reporting peaked in 2021 at $6,652 and has fallen 93.4% since, to $438 in 2025.
Across 31 payments — averaging $351.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$4K
- Sanofi-aventis U.S. LLC$3K
- Astellas Pharma US Inc$3K
- CSL Behring$912
- Bayer$205
- Novo Nordisk$129
- plus $383 from 8 others
Across 168 payments — averaging $675.82 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$92K
- Astellas Pharma Global Development$22K
What the payments were for
- Consulting fees$6,58060%
- Speaking & faculty fees$2,57224%
- Travel & lodging$9128%
- Food & beverage$8218%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $4,080 |
| Sanofi-aventis U.S. LLC | 2 | $2,676 |
| Astellas Pharma US Inc | 1 | $2,500 |
| CSL Behring | 1 | $912 |
| Bayer | 10 | $205 |
| Novo Nordisk | 2 | $129 |
| Novartis | 2 | $79 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $77 |
| ANI Pharmaceuticals, Inc. | 3 | $66 |
| Amgen | 2 | $47 |
| Boehringer Ingelheim | 2 | $40 |
| AstraZeneca | 2 | $28 |
| Mallinckrodt Hospital Products Inc. | 1 | $24 |
| GSK | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- THYMOGLOBULIN$2,676
How this compares
$10,885 in reported general payments places this provider in the 85th percentile of 68 nephrology providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 55 | $73,967 |
| OzempicSemaglutide | 21 | $30,500 |
| MounjaroTirzepatide | 11 | $18,520 |
| Envarsus XrTacrolimus | 14 | $6,651 |
| Valganciclovir Hcl | 12 | $5,971 |
| Mycophenolic AcidMycophenolate Sodium | 24 | $3,924 |
| Calcitriol | 67 | $3,063 |
| Nifedipine ErNifedipine | 77 | $3,027 |
| Tacrolimus | 22 | $3,027 |
| Cinacalcet Hcl | 29 | $2,393 |
| Mycophenolate Mofetil | 15 | $2,129 |
| Prednisone | 172 | $1,487 |
| Losartan Potassium | 87 | $1,122 |
| Tamsulosin Hcl | 50 | $936 |
| Rosuvastatin Calcium | 60 | $931 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $40 | $73,96755 claims |
| Novo NordiskOzempic | $129 | $30,50021 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 68 nephrology providers in New Mexico.
Other nephrology in Roswell
- Mekdess AbebeRoswell$4K
- Satyaki BanerjeeAlbuquerque$260K
- Catalina VoinescuSanta Fe$41K
- Christos ArgyropoulosAlbuquerque$32K
- Arun RajasekaranAlbuquerque$32K
- Jose HenaoLas Cruces$31K
- George Vasquez RiosAlbuquerque$25K
- Jayant KumarAlbuquerque$12K
- Luis Madera MarinAlbuquerque$7K
- Hector CastroAlbuquerque$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.